Vaccines as therapies for food allergies
- PMID: 34099110
- DOI: 10.1016/bs.apha.2021.01.003
Vaccines as therapies for food allergies
Abstract
Food allergy is a growing public health epidemic with few available treatments beyond allergen avoidance and rescue medications for accidental exposures. A major focus of therapeutic development for food allergies is allergen-specific immunotherapy (AIT) in which patients are exposed to increasing amounts of allergen in controlled dosing to induce desensitization or tolerance. The work of the past few decades has culminated in the recent FDA approval of a peanut product for oral AIT for peanut allergies. Despite these advances, current AIT protocols are cumbersome, take a long time to reach clinical benefit and often have significant side effects. Therefore, there is a great need to develop new therapeutics for food allergy. One area of research aims to improve AIT through the use of adjuvants which are substances traditionally added to vaccines to stimulate or direct a specific immune response. Adjuvants that induce Th1-polarized and regulatory immune responses while suppressing Th2 immunity have shown the most promise in animal models. The addition of adjuvants to AIT may reduce the amount and frequency of allergen required to achieve clinical benefit and may induce more long-lasting immune responses. In this chapter, we highlight examples of adjuvanted AIT and vaccines in development to treat food allergies.
Keywords: Allergy treatment; Food allergy; Immunotherapy and tolerance induction; Immunotherapy vaccines and mechanisms; Vaccines.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest J.J.O. is an inventor on patent application that has been submitted for a nanoemulsion adjuvant for the suppression of allergic disease that is described in this chapter (PCT/US2015/054943). This technology has been licensed to Blue Willow Biologics, and the University of Michigan has a financial interest in Blue Willow Biologics. J.J.L. has no conflicts of interest to disclose.
Similar articles
-
Mucosal Nanoemulsion Allergy Vaccine Suppresses Alarmin Expression and Induces Bystander Suppression of Reactivity to Multiple Food Allergens.Front Immunol. 2021 Feb 25;12:599296. doi: 10.3389/fimmu.2021.599296. eCollection 2021. Front Immunol. 2021. PMID: 33717078 Free PMC article.
-
Probiotics as adjuvants to mitigate adverse reactions and enhance effectiveness in Food Allergy Immunotherapy.Scand J Immunol. 2024 Dec;100(6):e13405. doi: 10.1111/sji.13405. Epub 2024 Oct 15. Scand J Immunol. 2024. PMID: 39407442 Review.
-
Eosinophilic gastrointestinal disorders and allergen immunotherapy: Lights and shadows.Pediatr Allergy Immunol. 2021 Jul;32(5):814-823. doi: 10.1111/pai.13458. Epub 2021 Feb 27. Pediatr Allergy Immunol. 2021. PMID: 33503273 Review.
-
Diving deep into fish allergen immunotherapy: Current knowledge and future directions.Asian Pac J Allergy Immunol. 2024 Mar;42(1):1-13. doi: 10.12932/AP-030923-1687. Asian Pac J Allergy Immunol. 2024. PMID: 38165149
-
Immunotherapy of Food Allergy: a Comprehensive Review.Clin Rev Allergy Immunol. 2019 Aug;57(1):55-73. doi: 10.1007/s12016-017-8647-y. Clin Rev Allergy Immunol. 2019. PMID: 28929421 Review.
Cited by
-
Leveraging an mRNA Platform for the Development of Vaccines Against Egg Allergy.Vaccines (Basel). 2025 Apr 24;13(5):448. doi: 10.3390/vaccines13050448. Vaccines (Basel). 2025. PMID: 40432060 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous